GILEAD SCIENCES, INC.

Gilead Sciences is expected to announce Q1 2025 earnings on April 24, 2025 [3], [6], [7]. The company anticipates strong results based on recent performance, including positive developments with its HIV prevention drug Lenacapavir and cirrhosis treatment Livdelzi [5]. Analysts predict an earnings beat [6] and the stock has a Zacks Rank #2 (Buy) [9], [10]. While the stock price has recently lagged behind the market [7], [10], Gilead is considered a strong dividend stock with growth potential in oncology and liver disease [4]. A shareholder proposal regarding a human rights policy will be voted on, potentially impacting Gilead's reputation and practices [11]. The company has been recognized for strong ESG performance [2].